- Previous Close
9,178.00 - Open
9,440.00 - Bid 9,472.00 x --
- Ask 9,514.00 x --
- Day's Range
9,440.00 - 9,440.00 - 52 Week Range
7,675.00 - 12,292.00 - Volume
11 - Avg. Volume
228 - Market Cap (intraday)
9.414T - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-1,039.87 - Earnings Date May 13, 2025
- Forward Dividend & Yield 44.83 (0.49%)
- Ex-Dividend Date Apr 28, 2025
- 1y Target Est
--
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed management as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular, renal, and gynecological diseases; collaboration agreement with Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
www.bayer.com90,587
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BAYER.BD
View MorePerformance Overview: BAYER.BD
Trailing total returns as of 3/17/2025, which may include dividends or other distributions. Benchmark is DAX P .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAYER.BD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAYER.BD
View MoreValuation Measures
Market Cap
9.15T
Enterprise Value
22.20T
Trailing P/E
--
Forward P/E
3.59
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.48
Price/Book (mrq)
0.71
Enterprise Value/Revenue
1.19
Enterprise Value/EBITDA
6.30
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.48%
Return on Assets (ttm)
3.00%
Return on Equity (ttm)
-7.82%
Revenue (ttm)
46.61B
Net Income Avi to Common (ttm)
-2.55B
Diluted EPS (ttm)
-1,039.87
Balance Sheet and Cash Flow
Total Cash (mrq)
8.09B
Total Debt/Equity (mrq)
127.36%
Levered Free Cash Flow (ttm)
5.47B